+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Pregabalin Market 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • July 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5393431
Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another. In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China's Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.





According to the market research, the sales value of Pregabalin in the Chinese market increased year by year from 2016 to 2020. Among them, the growth in sales value in 2019 was the most obvious. The sales value of Pregabalin reached CNY143 million in 2019, with an annual growth rate of 57.19%. The main reason is that Pregabalin was approved for new indications in China from 2018 to 2019, and the NMPA lifted the restriction on Pregabalin medical insurance indications in 2019, which led to a substantial increase in its sales volume and sales value. In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

The analyst expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to the analyst's market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

Topics Covered:

  • The impact of COVID-19 on China's Pregabalin market
  • Sales value of China's Pregabalin 2016-2020
  • Competitive landscape of China's Pregabalin market
  • Prices of Pregabalin in China
  • Prices of Pregabalin in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Pregabalin market
  • Prospect of China's Pregabalin market from 2021 to 2025
Frequently Asked Questions about the Chinese Pregabalin Market

What is the estimated value of the Chinese Pregabalin Market?

The Chinese Pregabalin Market was estimated to be valued at CNY 47.61 Million in 2016.

What is the growth rate of the Chinese Pregabalin Market?

The growth rate of the Chinese Pregabalin Market is 40.2%, with an estimated value of CNY 999.17 Million by 2025.

What is the forecasted size of the Chinese Pregabalin Market?

The Chinese Pregabalin Market is estimated to be worth CNY 999.17 Million by 2025.

Who are the key companies in the Chinese Pregabalin Market?

Key companies in the Chinese Pregabalin Market include Pfizer Ltd (LYRICA) and Qilu Pharmaceutical (Hainan) Co., Ltd. (Xisiping).

Table of Contents

1 Relevant Concepts of Pregabalin
1.1 Indications for Pregabalin
1.2 Development of Pregabalin in China
1.3 Governmental Approval of Pregabalin in China
1.4 The Impact of COVID-19 on Pregabalin sales in China
2 Sales of Pregabalin in China, 2016-2020
2.1 Sales Value of Pregabalin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pregabalin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Pregabalin by Dosage Form in China, 2016-2020
2.3.1 Capsules
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Pregabalin Manufacturers in China in 2020
3.1 Analysis of Market Share of Major Pregabalin Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Pfizer Ltd
3.2.1 Enterprise Profile
3.2.2 Sales of LYRICA (Pfizer Ltd’s Pregabalin) in China
3.3 Chongqing Saiwei Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Laireike (Chongqing Saiwei Pharmaceutical Co., Ltd.’s Pregabalin) in China
3.4 Qilu Pharmaceutical (Hainan) Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Xisiping (Qilu Pharmaceutical (Hainan) Co., Ltd.’s Pregabalin) in China
4 Prices of Pregabalin for Different Manufacturers in China, 2020-2021
4.1 Pfizer Ltd (LYRICA)
4.2 Chongqing Saiwei Pharmaceutical Co., Ltd. (Laireike)
4.3 Qilu Pharmaceutical (Hainan) Co., Ltd. (Xisiping)
5 Prospect of Chinese Pregabalin drug Market, 2021-2025
5.1 Influential Factors of Chinese Pregabalin Market Development
5.1.1 The Impact of COVID-19 on Chinese Pregabalin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Pregabalin Capsules Registration in China
Chart Sales Value of Pregabalin Capsules over the World
Chart Sales Value of Pregabalin Capsules in China, 2016-2020
Chart Sales Value of Pregabalin Capsules in China by Region, 2016-2020
Chart Sales Volume of Pregabalin Capsules in China, 2016-2020
Chart Sales Volume of Pregabalin Capsules in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Pregabalin Manufacturers in China, 2016-2020
Chart Sales Value and Volume of LYRICA in China, 2016-2020
Chart Sales Value and Volume of Laireike in China, 2016-2020
Chart Sales Value and Volume of Xisiping in China, 2016-2020
Chart Referential Prices of LYRICA in China, 2020-2021
Chart Referential Prices of Laireike in China, 2020-2021
Chart Referential Prices of Xisiping in China, 2020-2021
Chart Forecast on Sales Value of Pregabalin in China, 2021-2025
Chart Forecast on Sales Volume of Pregabalin in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Ltd (LYRICA)
  • Chongqing Saiwei Pharmaceutical Co., Ltd. (Laireike)
  • Qilu Pharmaceutical (Hainan) Co., Ltd. (Xisiping)

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...